Axogen, INC Form 4 insider transactions

Axogen's Chief Marketing Officer, Jens Kemp, sold 8,156 shares of common stock at a weighted average price of $31.208 to cover tax withholding obligations.

Axogen's EVP & General Counsel, Marc Began, sold 9,278 shares of common stock at a weighted average price of $31.208 to cover tax withholding obligations.

Axogen Director Paul Thomas sold 21,399 shares of common stock for a weighted average price of $29.614 per share on December 9, 2025, pursuant to a pre-arranged Rule 10b5-1 plan.

Axogen Director John Johnson executed pre-planned sales of all his common stock and exercised options, reducing his direct beneficial ownership to zero.

Axogen, Inc.'s CFO, Lindsey Marie Hartley, increased her direct beneficial ownership of common stock by 10,613 shares after exercising options and selling a portion.

Axogen's EVP and General Counsel, Marc Began, acquired 22,500 shares of common stock on December 4, 2025, as a result of performance criteria attainment.

Axogen's Chief Innovation Officer, Erick DeVinney, acquired 40,000 shares of common stock on December 4, 2025, issued upon the attainment of specific performance criteria.

Axogen's Chief Marketing Officer, Jens Kemp, acquired 22,500 shares of common stock through a performance-based award.

Axogen, Inc. CEO Michael D. Dale acquired 150,000 shares of common stock through the vesting of performance-based awards.

Axogen Director William P. Burke exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged trading plan.

Axogen Director William P. Burke exercised stock options and subsequently sold a significant number of common shares under a pre-arranged trading plan.

Axogen Director William P. Burke executed multiple option exercises and subsequent sales of common stock totaling 58,483 shares over two days under a pre-arranged trading plan.

Axogen Director William P. Burke sold 1,457 shares of common stock for a weighted average price of $18.018 per share on October 22, 2025, pursuant to a pre-arranged trading plan.

Axogen Director William P. Burke sold 736 shares of common stock for approximately $18.00 per share under a pre-arranged 10b5-1 trading plan.

Axogen Director William P. Burke sold 32,191 shares of common stock in early October 2025 through Rule 10b5-1 trading plans.

Axogen's Chief Innovation Officer, Erick DeVinney, reported the acquisition of 2,500 shares from performance criteria and a subsequent non-discretionary sale of 1,137 shares to cover tax obligations.

Axogen, Inc. Director John Johnson was granted 14,150 restricted stock units valued at $150,000 as part of his annual equity compensation, vesting on June 19, 2026.

Axogen, Inc. Director Joseph A. Tyndall was granted 14,150 restricted stock units valued at $150,000 as part of his annual equity compensation.

Axogen, Inc. Director Amy McBride Wendell has been granted 14,150 restricted stock units as part of her annual equity compensation for board service, vesting in June 2026.

Axogen, Inc. Director Kathy Johnson Weiler was granted 14,150 restricted stock units valued at $150,000 as part of her annual compensation, vesting in June 2026.

Axogen, Inc. Director William P. Burke was granted 14,150 restricted stock units as part of his annual equity compensation, valued at $150,000, which will vest on June 19, 2026.

Axogen, Inc. Director Alan M Levine was granted 14,150 restricted stock units as part of his annual equity compensation, valued at $150,000, vesting on June 19, 2026.

Axogen, Inc. Director Paul Thomas was granted 18,867 Restricted Stock Units (RSUs) as part of his annual equity compensation, valued at $200,000, which will vest on June 19, 2026.

Axogen Director Kathy Weiler sold 4,073 shares of common stock on June 9, 2025, at a weighted average price of $10.61 per share, primarily to satisfy tax obligations related to restricted stock unit vesting.

Axogen Director Alan M. Levine sold 4,073 shares of common stock on June 9, 2025, at a weighted average price of $10.61 per share, primarily to satisfy tax obligations related to restricted stock unit vesting.

Axogen, Inc. Director Amy McBride Wendell sold 4,073 shares of common stock on June 9, 2025, at a weighted average price of $10.61 per share to satisfy tax obligations related to restricted stock unit vesting.

Axogen, Inc. Director William P. Burke sold 4,073 shares of common stock for approximately $10.61 per share to satisfy tax obligations related to restricted stock unit vesting.

Axogen, Inc. Director Guido J. Neels sold 4,073 shares of common stock at a weighted average price of $10.61 per share to satisfy tax obligations related to the vesting of restricted stock units.

Axogen, Inc. Director John Johnson sold 4,073 shares of common stock on June 9, 2025, at a weighted average price of $10.61 per share to satisfy tax obligations related to restricted stock unit vesting.

Axogen, Inc. Director Joseph A. Tyndall sold 26,931 shares of common stock at a weighted average price of $10.72 per share on June 10, 2025, following the exercise of stock options.